AVE Science & Technology Co Ltd (688067) - Total Assets
Based on the latest financial reports, AVE Science & Technology Co Ltd (688067) holds total assets worth CN¥611.46 Million CNY (≈ $89.48 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688067 net assets for net asset value and shareholders' equity analysis.
AVE Science & Technology Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how AVE Science & Technology Co Ltd's total assets have evolved over time, based on quarterly financial data.
AVE Science & Technology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
AVE Science & Technology Co Ltd's total assets of CN¥611.46 Million consist of 54.4% current assets and 45.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.6% |
| Accounts Receivable | CN¥8.82 Million | 1.6% |
| Inventory | CN¥45.68 Million | 8.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥23.83 Million | 4.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how AVE Science & Technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688067 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AVE Science & Technology Co Ltd's current assets represent 54.4% of total assets in 2024, an increase from 53.2% in 2012.
- Cash Position: Cash and equivalents constituted 9.6% of total assets in 2024, down from 28.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 8.1% of total assets.
AVE Science & Technology Co Ltd Competitors by Total Assets
Key competitors of AVE Science & Technology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Teleflex Incorporated
NYSE:TFX
|
USA | $6.95 Billion |
|
Touchstone International Medical Science Co Ltd
SHG:688013
|
China | CN¥676.02 Million |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
Crossject
PA:ALCJ
|
France | €31.38 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
AVE Science & Technology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.05 | 6.56 | 2.40 |
| Quick Ratio | 4.47 | 5.51 | 1.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥336.21 Million | CN¥241.53 Million | CN¥66.80 Million |
AVE Science & Technology Co Ltd - Advanced Valuation Insights
This section examines the relationship between AVE Science & Technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.55 |
| Latest Market Cap to Assets Ratio | 0.51 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | CN¥561.00 Million |
| Market Capitalization | $284.59 Million USD |
Valuation Analysis
Below Book Valuation: The market values AVE Science & Technology Co Ltd's assets below their book value (0.51x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: AVE Science & Technology Co Ltd's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AVE Science & Technology Co Ltd (2012–2024)
The table below shows the annual total assets of AVE Science & Technology Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥561.00 Million ≈ $82.09 Million |
+0.77% |
| 2023-12-31 | CN¥556.69 Million ≈ $81.46 Million |
+1.28% |
| 2022-12-31 | CN¥549.65 Million ≈ $80.43 Million |
+0.37% |
| 2021-12-31 | CN¥547.61 Million ≈ $80.13 Million |
+84.65% |
| 2020-12-31 | CN¥296.57 Million ≈ $43.40 Million |
-0.29% |
| 2019-12-31 | CN¥297.44 Million ≈ $43.53 Million |
+15.44% |
| 2018-12-31 | CN¥257.67 Million ≈ $37.71 Million |
+14.99% |
| 2017-12-31 | CN¥224.08 Million ≈ $32.79 Million |
+6.01% |
| 2016-12-31 | CN¥211.37 Million ≈ $30.93 Million |
+26.93% |
| 2015-12-31 | CN¥166.53 Million ≈ $24.37 Million |
+3.48% |
| 2014-12-31 | CN¥160.93 Million ≈ $23.55 Million |
+14.01% |
| 2013-12-31 | CN¥141.16 Million ≈ $20.66 Million |
+15.86% |
| 2012-12-31 | CN¥121.83 Million ≈ $17.83 Million |
-- |
About AVE Science & Technology Co Ltd
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment China, Europe, the United States, Asia, Africa, and internationally. The company offers urine formed elements analyzer and related reagents, automatic urine ana… Read more